Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liren Cao

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancer Immunology, Immunotherapy : CII|April 20, 2024
A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinomaJing Xu, Wen Zhang, Jinlian Tong, et al.
Biochemical Pharmacology|November 23, 2006
Chain length dependence of the interactions of bisquaternary ligands with the Torpedo nicotinic acetylcholine receptorChris R J Carter, Liren Cao, Hideki Kawai, et al.
International Journal of Surgery (London, England)|May 29, 2025
Prolonged recurrence-free survival by autologous rectronectin-activated killer (RAK) cells in resected high-risk hepatocellular carcinoma: an experimental single-arm phase II trial (pilot study)Yiran Wang, Jing Xu, Luyao Zhang, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancer Immunology, Immunotherapy : CII|April 20, 2024
A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinomaJing Xu, Wen Zhang, Jinlian Tong, et al.
Biochemical Pharmacology|November 23, 2006
Chain length dependence of the interactions of bisquaternary ligands with the Torpedo nicotinic acetylcholine receptorChris R J Carter, Liren Cao, Hideki Kawai, et al.
International Journal of Surgery (London, England)|May 29, 2025
Prolonged recurrence-free survival by autologous rectronectin-activated killer (RAK) cells in resected high-risk hepatocellular carcinoma: an experimental single-arm phase II trial (pilot study)Yiran Wang, Jing Xu, Luyao Zhang, et al.
Pageof 2